Retatrutide

evidence score

fat loss

Research Only

122 studies

LY3437943triple agonistGLP-1 GIP glucagon agonist

Retatrutide is an investigational triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly. Phase II data demonstrated 24.2% average weight loss at 24 weeks — exceeding any approved therapy. Glucagon agonism adds hepatic fat mobilization and energy expenditure beyond dual GLP-1/GIP. Currently in Phase III trials for obesity and type 2 diabetes. Not available outside clinical trials; compounded versions circulate in gray market. Represents the next frontier of obesity pharmacology.

Evidence

Strong evidence

Safety

Unknown safety profile

Clinical Status

Phase III

Research Sync

Feb 19, 2026

Dosing

Typical

8 mg

1 mgRange12 mg

FrequencyOnce weekly subcutaneous (trial doses)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~6 days (estimated)

OnsetWeeks for weight loss; appetite suppression within days

DurationOngoing; effects reverse after discontinuation

Routes

subcutaneous

Evidence Score

Level A — Strong

122 studies indexed · 8 meta-analyses

Scoring Factors

Volume(40%)~42/100

Quality(30%)~55/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Retatrutide is currently categorized as a fat loss compound.

Evidence is strong (78/100) with a relatively mature body of research (122 indexed studies).

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Triple GLP-1/GIP/glucagon receptor agonist; adds hepatic fat mobilization and increased energy expenditure to GLP-1/GIP incretin effects

Practical Context

Strongest current signals

Level A: Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).
Level A: Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials.
Level A: Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.

Elevated caution signals

1 severe/high side effect flag